Takeda Pharmaceutical (NYSE:TAK) Insider Nicola Deidre Petal Greenway Sells 12,980 Shares of Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Nicola Deidre Petal Greenway sold 12,980 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $18.11, for a total transaction of $235,067.80. Following the transaction, the insider owned 40,049 shares of the company’s stock, valued at $725,287.39. The trade was a 24.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Nicola Deidre Petal Greenway also recently made the following trade(s):

• On Monday, August 10th, Nicola Deidre Petal Greenway sold 6,774 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $17.10, for a total transaction of $115,835.40.

Takeda Pharmaceutical Trading Up 1.7%

Shares of NYSE:TAK opened at $18.36 on Thursday. The company’s 50-day moving average price is $16.70 and its two-hundred day moving average price is $17.17. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90. The stock has a market capitalization of $58.84 billion, a PE ratio of 54.01 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.30. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The company had revenue of $7.50 billion during the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, equities analysts forecast that Takeda Pharmaceutical Co. will post 1.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold”.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Private Trust Co. NA lifted its holdings in Takeda Pharmaceutical by 84.7% during the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after purchasing an additional 783 shares during the last quarter. Parkside Financial Bank & Trust raised its position in shares of Takeda Pharmaceutical by 192.2% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after purchasing an additional 1,684 shares during the period. SHP Wealth Management bought a new position in shares of Takeda Pharmaceutical in the fourth quarter valued at about $42,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Takeda Pharmaceutical by 313.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after buying an additional 2,328 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Takeda Pharmaceutical by 56.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after buying an additional 1,292 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.